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ABSTRACT
Introduction Global progress in reducing malaria has 
stalled since 2015. Analysis of the situation is particularly 
needed in Nigeria, the country with by far the largest share 
of the burden, where approximately a quarter of all cases 
in the world are estimated to occur.
Methods We analysed data from three nationwide 
surveys (Malaria Indicator Surveys in 2010 and 2015 and 
a National Demographic and Health Survey in 2018), with 
malaria parasite prevalence in children under 5 years 
of age determined by sampling from all 36 states of 
Nigeria, and blood slide microscopy performed in the 
same accredited laboratory for all samples. Changes over 
time were evaluated by calculating prevalence ratio (PR) 
values with 95% CIs for each state, together with Mantel- 
Haenszel- adjusted PRs (PR
adj) for each of the six major 
geopolitical zones of the country.
Results Between 2010 and 2018, there were significant 
reductions in parasite prevalence in 25 states, but not in 
the remaining 11 states. Prevalence decreased most in 
southern zones of the country (South West PR
adj=0.53; 
South East PRadj=0.59; South South PRadj=0.51) and the 
North Central zone (PRadj=0.36). Changes in the north were 
less marked, but were significant and indicated overall 
reductions by more than 20% (North- West PRadj=0.74; 
North East PRadj=0.70). Changes in the south occurred 
mostly between 2010 and 2015, whereas those in the 
north were more gradual and most continued after 2015. 
Recent changes were not correlated with survey- reported 
variation in use of preventive measures.
Conclusion Reductions in malaria infection in children 
under 5 have occurred in most individual states in Nigeria 
since 2010, but substantial geographical variation in the 
timing and extent indicate challenges to be overcome to 
enable global malaria reduction.
INTRODUCTION
Currently, half of the global malaria burden 
is caused by Plasmodium falciparum in West 
Africa, most substantially in Nigeria, which 
is estimated to have approximately a quarter 
Key questions
What is already known?
 ► Despite previous progress, global reduction in ma-
laria has stalled in recent years.
 ► Nigeria is the country with the greatest burden of 
malaria infection.
 ► Nationwide surveys have indicated some reductions 
since 2010 but more analysis is needed to under-
stand the changes in detail.
What are the new findings?
 ► Analysis of community parasite prevalence in chil-
dren under 5 years of age from 2010, 2015 and 
2018 show informative trends for each of the 36 
states throughout the country.
 ► Between 2010 and 2018, there were significant de-
clines in prevalence in 25 of the states, most pro-
nounced in the southern and north- central zones of 
the country, although slight reductions in the more 
northern zones were also significant.
 ► Most of the reductions of prevalence in southern 
states occurred before 2015 and stalled or were 
partly reversed by 2018, while reductions in the 
north were more gradual and continued in the later 
period.
What do the new findings imply?
 ► This analysis indicates substantial subnational vari-
ation in the extent and timing of reductions in ma-
laria infection in young children, with an apparent 
dichotomy before and after 2015. The causes of the 
varying trends over time and among different states 
and zones of this large country need to be under-
stood in order that global goals of malaria reduction 
may be more realistically formulated.
 ► More detailed research on epidemiological deter-
minants and malaria prevention is needed, as use 
of preventive methods according to questionnaire- 
based surveys of household heads did not explain 
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of all cases in the world and a similar proportion of the 
overall malaria mortality.1 2 Under a ‘High burden to high 
impact’ initiative, WHO has issued a ‘wake- up call’ noting 
the need for urgent targeted action,3 particularly rele-
vant to Nigeria where WHO- estimated numbers of cases 
are increasing rather than reducing annually.2 3 Knowing 
how to reduce malaria in the future clearly requires 
understanding of current epidemiology, and identifica-
tion of changes that have already occurred.4
Notable reductions in malaria burden have been seen 
in some areas of West Africa, especially near the North 
Western edge of the endemic distribution in Senegal and 
The Gambia,5–7 encouraging studies to evaluate whether 
local elimination might become feasible in future.8 
However, there is an even more pressing need to under-
stand why the malaria burden remains high in other parts 
of the region, particularly in Nigeria. This is a priority to 
reduce global mortality and morbidity, and to reduce the 
main reservoir which may prevent other countries from 
achieving elimination due to continued importation of 
infections.9
Malaria surveillance at community level is important, 
as this has the potential to give unbiased indication of 
geographical variation and trends over time, but such 
data are lacking from most areas so that trends are only 
estimated by modelling.10 Separate small- scale surveys 
conducted in some communities in Nigeria over the past 
decade have indicated continuing high levels of malaria 
parasite infection (almost all P. falciparum), particularly 
in areas of the north with prevalence still exceeding 
60%,11–13 almost as high as reported in similar areas half 
a century or longer ago.14 15 In contrast, surveys in some 
areas in the south of the country report much lower infec-
tion prevalence, although with considerable local vari-
ation as illustrated by surveys in different communities 
within Lagos state.16–18 National Malaria Indicator Survey 
(MIS) data from 2010 and 2015 included slide micros-
copy data from children under 5 years of age, and these 
also showed regional variation and confirmed that states 
in the north of the country generally had higher preva-
lence than in the south.19 20 The 2015 data showed lower 
prevalence overall than was seen in the 2010 survey,20 
although analysis within the earlier survey report was 
limited to broad geographical zones rather than for each 
of the individual states sampled.
Recent availability of results from a National Demo-
graphic and Health Survey (NDHS) based on sampling 
from all 36 Nigerian states in 2018,21 together with the 
previous MIS data from 2010 and 2015, means that for the 
first time there are data for Nigeria from three nationwide 
surveys in which malaria parasite slide prevalence in chil-
dren under the age of 5 years has been measured. There 
are two important features of each of these three national 
surveys, for the purpose of critically analysing trends in 
infection. First, they were conducted at a similar period in 
each year, which minimises confounding of comparisons 
due to seasonal variation: 2010 MIS survey (October to 
December),20 2015 MIS Survey (October to November),19 
2018 NDHS survey (August to December).21 Second, but 
equally importantly, slide microscopy for each of these 
surveys was conducted under quality- controlled condi-
tions in the same accredited laboratory.
Here, we analysed the microscopy data from these three 
nationwide surveys, and evaluated changes over time by 
calculating prevalence ratios (PRs) between the surveys 
for each of the different states, together with adjusted 
PRs for each of the major geographical zones of the 
country. Emerging from this analysis are details of trends 
in reduction of malaria prevalence that are informative 
for formulating future intervention strategies. This also 
highlights opportunities for additional measurements 
to be made as part of future nationwide surveys, to help 




The population of Nigeria was estimated by the Nigerian 
Population Commission to have exceeded 182 million 
by late 2016, and is currently estimated by the United 
Nations (UN) as over 200 million, within a land area of 
9 23 768 km2. Malaria occurs throughout the country in 
highly diverse ecological zones existing in succession 
from south to north: Mangrove Swamp and Coastal Vege-
tation, Freshwater Swamp Forest, Lowland Rain Forest, 
Derived Savanna, Guinea Savannah, Sudan Savanna 
and Sahel Savanna. The country is divided into 36 states 
(figure 1) grouped into six geopolitical zones: North- 
East, North- Central, North- West, South- East, South- South 
and South- West, each of which contains between five and 
seven states (table 1), apart from the Federal Capital 
Territory incorporating Abuja. The National Malaria 
Elimination Programme of the Federal Ministry of 
Health provides policy and guidance for malaria control 
in Nigeria, while the implementation of interventions is 
done at the individual state level. The rate of implemen-
tation differs from one state to the other, influenced by 
factors including political will, resource mobilisation and 
partnership support, which are not easily quantifiable, 
although population- based surveys can provide some 
indices of reported coverage and use of implementations.
Data from nationwide population-based surveys
Three nationwide population- based surveys of malaria 
infection have been conducted in Nigeria, as part of 
two MIS and a recently published NDHS. Standardised 
methods of household cluster sampling were performed 
within the 2010 MIS survey (October to December),20 
2015 MIS Survey (October to November)19 and 2018 
NDHS survey (August to December).21 In the 2015 and 
2018 surveys random cluster sampling methodology 
was performed to select clusters of households within 
each of the separate states. In the 2010 survey, rando-
misation was performed within each of the six major 
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dispersal of sampled clusters within each of the 36 sepa-
rate states and overall sample sizes were only slightly 
lower than in the later surveys, leading to no substantial 
bias and broadly similar accuracy for the purpose of the 
current retrospective analysis. All data were generated 
under the Demographic and Health Surveys (DHS) 
Programme (https:// dhsprogram. com/), and have 
been made available (http:// mics. unicef. org/ surveys) 
with permission granted by the UNICEF Multiple Indi-
cator Cluster Surveys (MICS) team.
Malaria parasite microscopy
In all surveys, finger prick samples of capillary blood from 
children under 5 years of age (6–59 months) were taken to 
prepare thick and thin peripheral blood films for micros-
copy, using barcoded slides that were dried and stored 
in labelled slide boxes, and transported to the African 
Network for Drugs and Diagnostics Network (ANDI) 
Centre of Excellence for Malaria Diagnosis, College of 
Medicine, University of Lagos (a well- recognised accredited 
reference centre for multicentre diagnostic research with 
microscopy gold- standard measurement).22 On reception, 
the barcoded slides were individually scanned for reading 
into an electronic database created for the survey, and 
stained with 3% Giemsa using the WHO- recommended 
standard operating procedure number MM- SOP-04. 
Microscopical slide reading according to the protocol 
recommended by WHO for detection of malaria parasites 
was done independently by two WHO- certified malaria 
grade level 1 microscopists. To monitor the independence 
of the slide reading, the process was managed by a slide 
coordinator who received the microscopy results from each 
microscopist, and reviewed results for concordance. Where 
there was discordance in slide positivity, a third certified 
grade level 1 microscopist performed an independent slide 
read to provide resolution. The malaria microscopy data 
were entered independently by two data entry clerks to the 
Census Survey Processing System (CSPro software data-
base,US Census Bureau, USA), within the original survey 
protocols.
Figure 1 Geographical and temporal heterogeneity of malaria parasite prevalence in children under 5 years old in Nigeria. 
Data are analysed for all 36 states (excluding Borno state in 2015); the central Federal Capital Territory incorporating Abuja 
is not analysed as it could not be representatively sampled. The names of individual states are shown in the top map, and 
the grouping into six geopolitical zones is given in table 1. Data are derived from three previous surveys, made available for 
analysis from http://mics.unicef.org/surveys with permission by the UNICEF Multiple Indicator Cluster Surveys (MICS) team. 
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Statistical analysis of slide microscopy data from each of the 
different surveys
Slide microscopy data from the ANDI laboratory gener-
ated for the three separate nationwide surveys are 
analysed for trends in each of the 36 states nationwide. 
From the 2010 MIS survey, slide microscopy results for 
5084 children in the 36 states were analysed, giving a 
mean sample size of 141 per state. From the 2015 MIS 
survey, slide microscopy results for 5678 children in 35 
states were analysed, a mean sample size of 162 per state 
(Borno state was omitted from analysis for 2015 as it was 
not possible to perform representative sampling due to 
security challenges). From the 2018 NDHS survey, slide 
microscopy results for 8240 children in the 36 states were 
analysed, giving a mean sample size of 229 per state. 
The analysis considers proportions of children positive 
for any malaria parasites, the vast majority of infections 
being of the predominant parasite species Plasmodium 
falciparum in all surveys. Changes over time were analysed 
by calculating prevalence ratio (PR) values with 95% cCI 
between each of the different surveys for each of the 
different states, together with Mantel- Haenszel- adjusted 
PRadj and CI for each of the six major geographical zones 
of the country. Testing for correlations between temporal 
PRs and reported use of insecticide- treated nets (ITNs) 
was performed using Spearman’s non- parametric rank 
correlation across all states. Analyses of the data here 
were performed using SPSS version 25.0 and EPI- INFO, 
with graphical presentations using PRISM software.
Patient and public involvement
This study is a comparative analysis of three nationwide 
surveys conducted from 2010 to 2018 with sampling 
under previous protocols, and all analyses are based on 
metapopulation comparisons of data from 36 states, so 
it was not appropriate to involve patients or particular 
public communities in the design, conduct, reporting or 
dissemination plans.
RESULTS
From the nationwide surveys in 2010, 2015 and 2018, 
blood slide microscopy results allow estimation of malaria 
parasite infection prevalence in children under 5 years 
of age. The original survey reports indicated the overall 
nationwide prevalence as declining from 42% in 2010 to 
27% in 2015,19 20 with only a modest subsequent decline 
to 23% in 2018.21 Data were here analysed in more detail 
for all 36 states of Nigeria in each of the survey years 
(figure 1 and table 1), excluding Borno state in 2015 for 
which there were insufficient data. We checked denom-
inators so that only individuals having slides with a valid 
read result were included (a few individuals without 
a clear slide result were previously included in some 
previous denominators in original survey reports but 
were not counted in analysis here).
The malaria parasite prevalence in children under 
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geographical patterns and temporal differences (figure 1 
and table 1). Focusing on areas with high prevalence, 
17 of the states had prevalence of above 40% in 2010, 
many in northern and western areas but also some in 
other areas of the country, whereas in 2018 only one state 
had prevalence of above 40% (Kebbi state in the North- 
Western part of the country). Conversely, focusing on 
areas with less malaria, in 2010 only five states had preva-
lence of less than 20%, all in southern and eastern areas, 
whereas by 2018 there were 14 states with prevalence of 
less than 20% (figure 1 and table 1).
Statistical analysis of the data from each of the surveys 
uncovers more details on the magnitude and timing of 
the changes, and enable these to be evaluated not only for 
the major geopolitical zones of the country, but also for 
the individual states. Between 2010 and 2018 there were 
statistically significant declines in prevalence in 25 out of 
36 states, and no significant change in prevalence in the 
remaining 11 states (table 1 and figure 2). The declines 
were greatest in the three major southern zones of the 
country and in the North Central zone, with Mantel- 
Haenszel- adjusted PRs (PRadj with 95% CIs) indicating 
overall relative reduction by more than 40% (South West 
PRadj=0.53, 95% CI 0.46 to 0.61; South East PRadj=0.59, 
95% CI 0.49 to 0.72; South South PRadj=0.51, 95% CI 0.43 
to 0.61; North Central PRadj=0.36, 95% CI 0.32 to 0.42). 
Although the declines in the northern zones were less 
marked and not significant in many states, they were still 
significant overall, indicating relative reduction by more 
than 20% (North- West PRadj=0.74, 95% CI 0.68 to 0.81; 
North East PRadj=0.70, 95% CI 0.61 to 0.81).
Analysis of the changes between each of the successive 
surveys showed significant variation in the trends over 
time (figure 3). Out of 35 states analysed (Borno was 
excluded for 2015), 20 states had statistically significantly 
lower prevalence in 2015 vs 2010 (figure 3), while only 
two states had significantly higher prevalence in 2015 
(Adamawa and Taraba, in the North East). The reduction 
in prevalence between 2010 and 2015 was significant in 
all of the major zones of the country, except for the North 
East (figure 3). There was a greater relative reduction in 
the south of the country, so that the overall heteroge-
neity among states nationwide was increased, as reflected 
by the coefficient of variation (SD divided by the mean, 
increasing from 0.411 in 2010 to 0.558 in 2015).
The comparison of subsequent differences between 
2015 and 2018 in these 35 states shows that 9 states had 
statistically significantly lower prevalence in 2018, while 4 
states had significantly higher prevalence in 2018 (figure 3 
and table 1). In contrast with the previous period, there 
was minimal reduction in prevalence in southern areas 
between 2015 and 2018, and a slight increase was seen 
in the South West zone (adjusted PR=1.21, 95% CI 1.01 
to 1.43), and in some other individual states. However, 
there were reductions in prevalence in many of the 
northern states between 2015 and 2018, and significant 
declines were seen overall in the North Central zone 
(PRadj=0.56, 95% CI 0.48 to 0.56) and North- West zone 
(PRadj=0.90, 95% CI 0.83 to 0.98), while the decline was 
of borderline significance in the North East (PRadj=0.85, 
95% CI 0.72 to 1.00). These modest but significant 
declines in prevalence in northern areas, where malaria 
burden has historically been highest, slightly reduced the 
overall heterogeneity across states nationwide (signified 
by a coefficient of variation of 0.558 in 2015 decreasing 
to 0.454 in 2018).
The heterogeneity in malaria trends in different parts 
of Nigeria should be considered in relation to changes 
in coverage and use of antimalarial prevention and treat-
ment. Although it is difficult to obtain accurate data 
on local variation at the population level, the MIS and 
NDHS surveys included relevant questionnaires that at 
least allow trends in the household respondent data to 
be investigated. Nationwide, there was a substantial and 
continued increase in the reported proportion of malaria 
cases that respondents claimed were treated with a recom-
mended artemisinin- based combination therapy (ACT), 
from only 6.0% (in 2010) to 37.6% (in 2015) and 52.0% 
(in 2018).19–21 As the proportions increased in parallel 
in all six major zones of the country, reported ACT use 
does not explain the observed variation in malaria trends 
nationwide including the recent reversals in parts of the 
country. Over the same period the proportions of house-
holds with respondents reporting ownership of ITNs 
increased nationwide from 42.0% (in 2010), to 69.0% 
(in 2015) but then declined to 60.6% (in 2018).19–21 As 
ownership does not equate to use, it is notable that the 
reported overall level of use by children under 5 years 
of age increased slightly from 37.3% in 2015 to 43.2% 
in 2018,21 so we investigated whether variation in levels 
of use in each state (tabulated in online supplemental 
table 1) correlated with recent changes in malaria prev-
alence. The PR in 2018 compared with 2015 across indi-
vidual states (as shown in figure 3 and tabulated in online 
supplemental table 1) did not correlate significantly with 
the reported ITN use by children under 5 years of age in 
these states in 2015 (Spearman’s r=−0.25, p=0.15), or in 
2018 (Spearman’s r=−0.09, p=0.61), or with the change 
in ITN use reported between the surveys (Spearman’s 
r=0.26, p=0.15).
DISCUSSION
Although Nigeria is the country with by far the largest 
burden of malaria globally,2 it is now clear that over the 
past decade there have been significant reductions in 
malaria infection prevalence in children under 5 years 
of age in all the major geopolitical zones of the country, 
and in most of the individual states. However, the rela-
tive reductions have been modest, and show substantial 
subnational variation in their timing and extent. This 
highlights major ongoing challenges to achieve and 
sustain reductions in malaria infection, vital for global 
targets.
Considering where malaria control is most needed, it 
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malaria burdens that are among the highest globally 
had a similar prevalence in 2018 compared with 2010. 
It is of highest priority to understand reasons for the 
lack of decline in malaria infection in children under 
5 years of age in these states, and to identify whether 
targeted increases in coverage of existing interven-
tions will be effective, or whether new interventions are 
required. Conversely, many states in southern areas of 
the country had substantially reduced prevalence in 2015 
compared with 2010, but no further reduction was seen 
by 2018, which raises concerns on how to consolidate and 
continue to reduce malaria after some initial progress. It 
was previously shown that variation in prevalence among 
states in the 2015 survey was greater than the subnational 
variation seen in comparable DHS surveys of infection 
in young children in other highly endemic West African 
Figure 2 Prevalence ratios (with 95% CIs) comparing malaria parasite infection in under 5- year old children in 2018 with 2010 
in each state and geographical zone in Nigeria. Although there was marked variation, significant declines in prevalence were 
seen in many states, indicated by ratios with 95% CIs to the left of the line. For each of the six major geographical zones of 
the country, the overall Mantel- Haenszel- adjusted prevalence ratio (PRadj) is plotted with a purple diamond symbol (with 95% 
CIs), showing significant overall declines: North- West PRadj=0.74 (0.68–0.81); North East PRadj=0.70 (0.61–0.81); North central 
PRadj=0.36 (0.32–0.42); South West PRadj=0.53 (0.46–0.61); South East PRadj=0.59 (0.49–0.72); South South PRadj=0.51 (0.43–
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countries,23 emphasising the need to understand diver-
gent trends occurring within Nigeria.
It is important to highlight varying levels and timing 
of declines in malaria prevalence in young children, 
but also to acknowledge that there may be multiple 
causes. The NDHS survey- reported use of appropriate 
ACT therapy for malaria case management was higher 
in 2018 than in the previous MIS surveys, although 
the actual use may be lower than reported, and non- 
recommended or unofficial therapy is very common.21 
Although distribution and ownership of donated ITNs 
increased in most areas between 2010 and 2015, there 
was a slight decline in reported ownership of ITNs by 
2018, and levels of use remain low in many communities 
Figure 3 Decrease in malaria prevalence in under 5- year old children shows significant heterogeneity over time and 
geographical area. Prevalence ratios (with 95% CIs) compare the malaria parasite infection in under 5- year old children in 
individual states and geographical zones of Nigeria in the intervals between 2010 and 2015 (left hand panel), and between 
2015 and 2018 (right hand panel). For each of the six major geographical zones of the country, the overall Mantel- Haenszel- 
adjusted prevalence ratio (PRadj) is plotted with a purple diamond symbol with 95% CIs. Between 2010 and 2015, significant 
declines are seen in all zones, except the North East where the decline is borderline significant, and the declines are more 
marked in the South of the country. Between 2015 and 2018, significant declines were seen overall in North central zone and 
North- West zone, borderline significant in North East. (Data for Lagos state are not plotted as there was an indefinite PR due to 
zero positive slides in 2015, and Borno state is not included due to lack of data for 2015). All numbers and P values are given in 
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throughout the country. Although there was no signifi-
cant correlation between reported ITN use in children 
under 5 and the variable trends in malaria infection in 
this age group between 2015 and 2018, this does not indi-
cate that variation in ITN use is unimportant, as reported 
levels of use are often not reliable indicators of actual 
use. Overall, although improved tools will be needed 
in future, it is clear that substantive gains should still be 
achieved by more effective implementation of current 
policies on prevention and treatment, following WHO 
recommendations.
In addition to established methods, seasonal malaria 
chemoprevention (SMC) targeted to children under 
5 years of age became a policy from 2014 onwards in 
several of the northern states where malaria prevalence 
has remained high, but only very limited implemen-
tation occurred in a few states before the 2018 survey. 
Community- based trials in diverse areas of West Africa 
where malaria is highly seasonal have demonstrated that 
the effect of intensively- delivered SMC on clinical inci-
dence and parasite prevalence should be substantial.24–26 
Although there are many challenges to optimal imple-
mentation in northern Nigeria where malaria is most 
seasonal, it is notable that SMC has been safely and effec-
tively delivered to children up to the age of 10 years in 
trials in Senegal,27 so potential benefits of expanding 
the age coverage in Nigeria should be considered, 
while continuing efforts to establish effective delivery to 
younger children as currently intended.
Beyond disease- specific interventions, socioeconomic 
development is needed to sustainably reduce malaria. In 
previous analysis of data from the 2015 MIS survey, many 
correlating variables were associated with malaria preva-
lence, including limited education of household heads 
and mothers, and unimproved housing.12 Although 
confounding socioeconomic interactions prevent impu-
tation of causality of individual determinants in such a 
survey, data from multiple studies elsewhere provide a 
consensus that house quality is a major determinant of 
malaria infection risk,28 29 as prevention of mosquito 
entry is a major means to reduce exposure. This is 
worthy of attention for research in Nigeria, as improve-
ments in house design and construction are needed. 
Such improvements could bring the most substantive 
benefits to communities in rural areas, and it should be 
noted that they are separate to more general effects of 
urbanisation in locally reducing malaria.30 In addition, 
epidemiological differences among zones and states may 
require more tailored intervention approaches. Aside 
from known ecological variation, and potential impacts 
of ongoing climate change that need to be determined, 
some large areas of irrigation that support farming 
may extend seasonal breeding of vector mosquitoes . 
Uncovering the local determinants of varying malaria 
transmission in each area may guide more appropriate 
interventions, and requires more formative research 
going forward.
Unscheduled disruptions also contribute to the overall 
challenges of malaria control. Sustained interventions in 
some states of the North East are have been difficult due 
to security challenges which impede access of commodi-
ties and health personnel for implementation and moni-
toring. More recently, disruption due to the Coronavirus 
pandemic is likely to cause reversals to the moderate 
reductions in malaria described here,31 and has already 
caused plans for the next national MIS that was sched-
uled for 2020 to be postponed. Given this setback, it is 
important to plan for more informative surveillance of 
malaria in Nigeria in future. For example, to supplement 
slide microscopy, molecular detection assays on DNA 
from dried blood spots would offer more highly sensitive 
and specific detection of infection, and would improve 
detection of rarer malaria parasite species that tend to 
occur as coinfections along with P. falciparum. The same 
samples could be used for monitoring of antimalarial 
drug- resistance allele frequency changes, which will be a 
vital part of resistance management to direct policy on 
drugs to be used for antimalarial therapy32 33 as well as 
other drugs for targeted prevention by SMC for young 
children27 34 and intermittent preventive treatment 
for pregnant women34–36 and potentially for infants. 
The benefits of such additional survey measures would 
become increasingly apparent over time, given the incre-
mental value of repeated surveys that apply standardised 
laboratory methods as illustrated here.
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Supplementary Table 1 Datasheet. Malaria parasite slide microscopy data from three DHS surveys and statistical analyes of prevlence ratios over time
2010 (MIS data) 2015 (MIS data) 2018 (NDHS data)
State Slide pos %' Total Slide pos Slide neg Slide pos % Total Slide pos Slide neg Slide pos % Total Slide pos Slide neg
Benue 56.5 207 117 90 44.5 230 102 128 20.1 265 53 212
Kogi 40 125 50 75 5.4 131 7 124 12.7 105 13 92
Kwara 58.8 85 50 35 26.4 121 32 89 25.4 147 37 110
Nasarawa 35.3 116 41 75 35.9 99 36 63 20.2 132 27 105
Niger 66.1 180 119 61 33.5 258 86 172 13.6 289 39 250
Plateau 32.2 121 39 82 35.8 210 75 135 21.4 165 35 130
Borno 25.3 146 37 109 10.1 258 287 29
Adamawa 19.9 141 28 113 34.7 135 47 88 21.1 188 40 148
Bauchi 44 250 110 140 19.6 238 47 191 30.6 241 74 167
Gombe 22.5 151 34 117 28.6 105 30 75 30.3 143 43 100
Taraba 17.7 96 17 79 42.9 119 51 68 20.8 159 33 126
Yobe 42.3 123 52 71 18.9 160 30 130 13.3 247 33 214
Jigawa 42.3 104 44 60 27.9 308 86 222 35.7 291 104 187
Kaduna 28.4 229 65 164 36.7 233 86 147 33.0 454 150 304
Kano 39.8 289 115 174 27.7 368 102 266 32.4 488 158 330
Katsina 52 277 144 133 27.8 445 124 321 25.5 475 121 354
Kebbi 72 93 67 26 63.6 157 100 57 52.2 189 99 90
Sokoto 37.5 168 63 105 46.6 157 73 84 36.4 163 59 104
Zamfara 66.7 102 68 34 62.6 185 116 69 35.7 254 91 163
Abia 39.8 98 39 59 8.2 64 5 59 13.5 123 17 106
Anambra 14.2 134 19 115 10.2 134 14 120 8.8 370 33 337
Ebonyi 31.6 117 37 80 30 120 36 84 30.5 283 86 197
Enugu 25.3 146 37 109 10.5 84 9 75 17.4 162 28 134
Imo 25 144 36 108 5.1 98 5 93 7.8 213 17 196
Akwa Ibom 31.7 205 65 140 22.8 95 22 73 23.2 149 35 114
Bayelsa 24.4 123 30 93 31.4 102 32 70 12.5 74 9 65
Cross River 41.3 121 50 71 26.1 82 21 61 19.5 71 14 57
Delta 27.7 184 51 133 20.4 111 23 88 17.0 170 29 141
Edo 60.6 132 80 52 18.6 56 10 46 14.7 96 14 82
Rivers 20.3 192 39 153 7.3 184 13 171 11.2 301 34 267
Ekiti 40 65 26 39 28.8 75 22 53 32.3 108 35 73
Lagos 10.3 107 11 96 0 246 0 246 1.8 485 9 476
Ogun 55.6 45 25 20 14.7 94 14 80 21.6 236 51 185
Ondo 54.4 79 43 36 21.3 121 26 95 33.5 117 39 78
Osun  62.9 62 39 23 33.4 133 44 89 27.7 201 56 145
Oyo 42.5 127 54 73 19.2 220 42 178 23.8 399 95 304
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Prevalence Ratio (PR) 2018 versus 2010: Prevalence Ratio (PR) 2015 versus 2010:
State PR lower 95% upper 95% P (Fisher's) PR lower 95% upper 95% P (Fisher's)
Benue 0.35 0.27 0.46 0.00000001 0.78 0.65 0.95 0.013
Kogi 0.31 0.18 0.54 0.0000029 0.13 0.06 0.28 0.00000001
Kwara 0.43 0.31 0.60 0.0000006 0.45 0.32 0.64 0.000004
Nasarawa 0.58 0.38 0.88 0.0103 1.03 0.72 1.47 0.887
Niger 0.20 0.15 0.28 0.00000001 0.50 0.41 0.62 0.00000001
Plateau 0.66 0.45 0.97 0.041 1.11 0.81 1.52 0.55
Borno 0.40 0.26 0.62 0.000059
Adamawa 1.07 0.70 1.65 0.785 1.75 1.17 2.62 0.007
Bauchi 0.70 0.55 0.88 0.0028 0.45 0.34 0.60 0.00000001
Gombe 1.34 0.91 1.97 0.147 1.27 0.83 1.93 0.305
Taraba 1.17 0.69 1.99 0.627 2.42 1.50 3.91 0.0001
Yobe 0.32 0.22 0.46 0.00000001 0.52 0.35 0.76 0.0007
Jigawa 0.85 0.64 1.11 0.241 0.66 0.50 0.88 0.007
Kaduna 1.16 0.91 1.49 0.223 1.30 1.00 1.70 0.059
Kano 0.81 0.67 0.99 0.0431 0.70 0.56 0.87 0.0015
Katsina 0.49 0.41 0.59 0.00000001 0.54 0.44 0.65 0.00000001
Kebbi 0.73 0.60 0.88 0.0019 0.88 0.74 1.05 0.211
Sokoto 0.97 0.73 1.28 0.821 1.24 0.96 1.60 0.115
Zamfara 0.54 0.43 0.67 0.00000016 1.05 0.89 1.23 0.662
Abia 0.35 0.21 0.58 0.000012 0.20 0.08 0.47 0.000004
Anambra 0.63 0.37 1.07 0.098 0.74 0.39 1.41 0.458
Ebonyi 0.96 0.70 1.32 0.812 0.95 0.65 1.39 0.888
Enugu 0.68 0.44 1.06 0.094 0.42 0.21 0.83 0.0097
Imo 0.31 0.18 0.52 0.0000049 0.20 0.08 0.50 0.00004
Akwa Ibom 0.74 0.52 1.05 0.095 0.73 0.48 1.11 0.135
Bayelsa 0.50 0.25 0.99 0.043 1.29 0.84 1.96 0.294
Cross River 0.48 0.29 0.80 0.0025 0.61 0.41 0.95 0.0247
Delta 0.62 0.41 0.92 0.022 0.75 0.49 1.15 0.213
Edo 0.24 0.15 0.40 0.00000001 0.29 0.16 0.53 0.00000007
Rivers 0.56 0.36 0.85 0.0089 0.35 0.19 0.63 0.0003
Ekiti 0.81 0.54 1.21 0.328 0.73 0.46 1.16 0.214
Lagos 0.20 0.08 0.47 0.00036 0.00 nd nd 0.0000014
Ogun 0.39 0.27 0.56 0.000012 0.27 0.15 0.46 0.0000015
Ondo 0.61 0.44 0.85 0.0049 0.39 0.27 0.59 0.0000022
Osun  0.44 0.33 0.59 0.00000093 0.53 0.39 0.72 0.00016
Oyo 0.56 0.43 0.73 0.000072 0.45 0.32 0.63 0.0000057
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Prevalence Ratio 2018 versus 2015: ITN use 2015 ITN use 2018 Change in ITN use
State PR lower 95% upper 95% P (Fisher's) % % %
Benue 0.45 0.34 0.60 0.00000001 24.6 52 27.4
Kogi 2.32 0.96 5.60 0.062 22.3 48.2 25.9
Kwara 0.95 0.63 1.43 0.89 16.6 30.4 13.8
Nasarawa 0.56 0.37 0.86 0.011 44.4 51.2 6.8
Niger 0.41 0.29 0.57 0.00000004 38 29 -9
Plateau 0.59 0.42 0.84 0.0029 38.4 35 -3.4
Borno
Adamawa 0.61 0.43 0.88 0.0077 31.6 42.6 11
Bauchi 1.55 1.13 2.14 0.0063 59.2 48.7 -10.5
Gombe 1.05 0.71 1.56 0.89 33.6 40.9 7.3
Taraba 0.48 0.33 0.70 0.00011 27.3 20.2 -7.1
Yobe 0.71 0.45 1.12 0.16 55.9 53.7 -2.2
Jigawa 1.28 1.01 1.62 0.044 75.5 87.1 11.6
Kaduna 0.89 0.72 1.11 0.351 61.6 54.3 -7.3
Kano 1.17 0.95 1.44 0.15 43.8 65.1 21.3
Katsina 0.91 0.74 1.13 0.41 53.6 64.7 11.1
Kebbi 0.82 0.69 0.98 0.038 37.6 81.6 44
Sokoto 0.78 0.60 1.01 0.069 48.7 52.6 3.9
Zamfara 0.57 0.47 0.70 0.00000003 56.6 43.8 -12.8
Abia 1.77 0.68 4.58 0.339 7 22.7 15.7
Anambra 0.85 0.47 1.54 0.605 24.1 18.2 -5.9
Ebonyi 1.01 0.73 1.40 1 50 61.6 11.6
Enugu 1.61 0.80 3.26 0.193 14.1 19.9 5.8
Imo 1.56 0.59 4.12 0.477 5.9 24.8 18.9
Akwa Ibom 1.01 0.64 1.62 1 36.8 25.9 -10.9
Bayelsa 0.39 0.20 0.76 0.00036 18.2 29.2 11
Cross River 0.77 0.43 1.40 0.443 49.6 39.6 -10
Delta 0.82 0.50 1.35 0.438 18.1 28.5 10.4
Edo 0.82 0.39 1.71 0.648 10.7 27.7 17
Rivers 1.6 0.87 2.95 0.155 31.7 21.3 -10.4
Ekiti 1.1 0.71 1.72 0.746 27.3 22.2 -5.1
Lagos nd nd nd 0.033 11.1 12.8 1.7
Ogun 1.45 0.84 2.49 0.219 12.2 35.9 23.7
Ondo 1.55 1.01 2.38 0.043 20.1 53.1 33
Osun  0.84 0.61 1.17 0.33 21.4 26.8 5.4
Oyo 1.25 0.90 1.72 0.189 31.4 38.9 7.5
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